[go: up one dir, main page]

GB1518683A - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB1518683A
GB1518683A GB28246/75A GB2824675A GB1518683A GB 1518683 A GB1518683 A GB 1518683A GB 28246/75 A GB28246/75 A GB 28246/75A GB 2824675 A GB2824675 A GB 2824675A GB 1518683 A GB1518683 A GB 1518683A
Authority
GB
United Kingdom
Prior art keywords
july
skin permeation
alkaloid
ergot
dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB28246/75A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of GB1518683A publication Critical patent/GB1518683A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1518683 Skin permeation compositions SANDOZ Ltd 4 July 1975 [5 July 1974] 28246/75 Heading A5B A skin permeation preparation comprises (a) at least one active ingredient at least partly dissolved in a carrier comprising (b) a C 11 -C 24 aliphatic alcohol which is liquid at 25‹C, and (c) an amphoteric or anionic surfactant, the concentration of (c) being at least 5% by wt. in the composition and such that it would give a pH of 4 to 8 if dissolved in water at the same concentration. The active agent (a) may be a quinazoline, an ergot alkaloid, an hydrogenated derivative of an ergot peptide alkaloid or 4-(1-methyl-4-piperidylidene)-4H-benzo [4, G] cyclohepta [1, 2-b]- thiophen-10 (9H)-one.
GB28246/75A 1974-07-05 1975-07-04 Pharmaceutical compositions Expired GB1518683A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH931274 1974-07-05

Publications (1)

Publication Number Publication Date
GB1518683A true GB1518683A (en) 1978-07-19

Family

ID=4350618

Family Applications (1)

Application Number Title Priority Date Filing Date
GB28246/75A Expired GB1518683A (en) 1974-07-05 1975-07-04 Pharmaceutical compositions

Country Status (14)

Country Link
JP (1) JPS5132724A (en)
AU (1) AU8280175A (en)
BE (1) BE831042A (en)
DE (1) DE2528516A1 (en)
ES (1) ES439113A1 (en)
FR (1) FR2276832A1 (en)
GB (1) GB1518683A (en)
HU (1) HU170215B (en)
IL (1) IL47634A (en)
NL (1) NL7507798A (en)
NZ (1) NZ178011A (en)
SE (1) SE7507414L (en)
YU (1) YU170475A (en)
ZA (1) ZA754304B (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4752612A (en) * 1983-07-01 1988-06-21 Nitto Electrical Industrial Co., Ltd. Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
GB2230444A (en) * 1989-04-19 1990-10-24 Ritchie Swanson John Topical therapeutic compositions containing betaine surfactant
US5059427A (en) * 1987-05-15 1991-10-22 Sansho Co., Ltd. Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or salt thereof
US5128376A (en) * 1983-07-01 1992-07-07 Nitto Denko Corporation Method for percutaneously administering physiologically active agents using an adjuvant a solvent and a diol moderator
US5219877A (en) * 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5652228A (en) * 1993-11-12 1997-07-29 The Procter & Gamble Company Topical desquamation compositions
US5681852A (en) * 1993-11-12 1997-10-28 The Procter & Gamble Company Desquamation compositions
US5807820A (en) * 1988-05-13 1998-09-15 Novartis Ag Cyclosporin compositions for topical application
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
US6005135A (en) * 1996-03-21 1999-12-21 Exxon Chemical Patents Inc. Water-borne polymeric vehicle for coating compositions containing an amine or ammonium salt of phenolic ester alcohols
EP1011610A4 (en) * 1997-08-15 2004-08-18 Scandinavian American Imp Exp Skin care compositions and use
EP2223703A4 (en) * 2007-11-22 2011-01-19 Medrx Co Ltd External preparation composition comprising fatty acid-based ionic liquid as active ingredient
EP2570116A1 (en) * 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
EP2570115A1 (en) * 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US9682127B2 (en) 2005-02-03 2017-06-20 Intarcia Therapeutics, Inc. Osmotic delivery device comprising an insulinotropic peptide and uses thereof
US9724293B2 (en) 2003-11-17 2017-08-08 Intarcia Therapeutics, Inc. Methods of manufacturing viscous liquid pharmaceutical formulations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
USD835783S1 (en) 2016-06-02 2018-12-11 Intarcia Therapeutics, Inc. Implant placement guide
US10159714B2 (en) 2011-02-16 2018-12-25 Intarcia Therapeutics, Inc. Compositions, devices and methods of use thereof for the treatment of cancers
US10231923B2 (en) 2009-09-28 2019-03-19 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US10527170B2 (en) 2006-08-09 2020-01-07 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54163810A (en) * 1978-06-14 1979-12-26 Mundipharma Ag Gel composition for local coating
JPS56159310A (en) * 1980-05-14 1981-12-08 Showa Denko Kk Preparation of monofilament having high strength and knot strength
FR2483235A1 (en) * 1980-05-28 1981-12-04 Fabre Sa Pierre TOPICAL COMPOSITIONS CONTAINING RYE AND VINCA ROSEA ERGOT ALKALOIDS FOR THE TREATMENT OF HYPERSEBORRHOES
JPS59216825A (en) * 1983-05-23 1984-12-06 Takeda Chem Ind Ltd External drug for transcutaneous absorption
US4590190A (en) * 1983-07-01 1986-05-20 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
JPS6013720A (en) * 1983-07-01 1985-01-24 Nitto Electric Ind Co Ltd Percutaneous administration of physiological activator using adjuvant, solvent and diol modulator
JPH0735331B2 (en) * 1986-01-16 1995-04-19 久光製薬株式会社 External gel formulation
JPH0735332B2 (en) * 1986-02-25 1995-04-19 久光製薬株式会社 Cream formulation for external use
JPH0759519B2 (en) * 1987-02-23 1995-06-28 株式会社資生堂 Transdermal absorption enhancer and external preparation for skin containing the same
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
DE3710216A1 (en) * 1987-03-27 1988-10-06 Rentschler Arzneimittel USE OF DIHYDROERGOTAMINE AND ITS SALTS FOR LOCAL TREATMENT OF TROPHIC DISORDERS
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
ATE164080T1 (en) * 1990-05-10 1998-04-15 Bechgaard Int Res PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLES AND N-ETHYLENE GLYCOLS
IL98747A0 (en) * 1991-07-05 1992-07-15 Yissum Res Dev Co Ophthalmic compositions
PT1666026E (en) † 1999-02-08 2012-03-15 Intarcia Therapeutics Inc Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
JP2012020991A (en) 2010-06-16 2012-02-02 Takasago Internatl Corp Transdermal absorption promoter, and external skin formulation thereof
EP3395369A1 (en) 2014-10-30 2018-10-31 Asahi Kasei Kabushiki Kaisha Transdermal absorption enhancer and transdermal absorption enhancement aid

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752612A (en) * 1983-07-01 1988-06-21 Nitto Electrical Industrial Co., Ltd. Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
US5128376A (en) * 1983-07-01 1992-07-07 Nitto Denko Corporation Method for percutaneously administering physiologically active agents using an adjuvant a solvent and a diol moderator
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US5059427A (en) * 1987-05-15 1991-10-22 Sansho Co., Ltd. Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or salt thereof
US5073375A (en) * 1987-05-15 1991-12-17 Sansho Co., Ltd. Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or salt thereof
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5807820A (en) * 1988-05-13 1998-09-15 Novartis Ag Cyclosporin compositions for topical application
GB2230444B (en) * 1989-04-19 1993-12-08 Ritchie Swanson John Therapeutic compositions.
GB2230444A (en) * 1989-04-19 1990-10-24 Ritchie Swanson John Topical therapeutic compositions containing betaine surfactant
US5219877A (en) * 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5652228A (en) * 1993-11-12 1997-07-29 The Procter & Gamble Company Topical desquamation compositions
US5681852A (en) * 1993-11-12 1997-10-28 The Procter & Gamble Company Desquamation compositions
US5849728A (en) * 1993-11-12 1998-12-15 The Procter & Gamble Company Desquamation compositions
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
US6005135A (en) * 1996-03-21 1999-12-21 Exxon Chemical Patents Inc. Water-borne polymeric vehicle for coating compositions containing an amine or ammonium salt of phenolic ester alcohols
EP1011610A4 (en) * 1997-08-15 2004-08-18 Scandinavian American Imp Exp Skin care compositions and use
US9724293B2 (en) 2003-11-17 2017-08-08 Intarcia Therapeutics, Inc. Methods of manufacturing viscous liquid pharmaceutical formulations
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US10363287B2 (en) 2005-02-03 2019-07-30 Intarcia Therapeutics, Inc. Method of manufacturing an osmotic delivery device
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US9682127B2 (en) 2005-02-03 2017-06-20 Intarcia Therapeutics, Inc. Osmotic delivery device comprising an insulinotropic peptide and uses thereof
US10527170B2 (en) 2006-08-09 2020-01-07 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
AU2008327436B2 (en) * 2007-11-22 2013-09-05 Medrx Co., Ltd. External preparation composition comprising fatty acid-based ionic liquid as active ingredient
CN101909651B (en) * 2007-11-22 2013-11-06 美德阿利克斯株式会社 External preparation composition comprising fatty acid-based ionic liquid as active ingredient
US8623387B2 (en) 2007-11-22 2014-01-07 Medrx Co., Ltd. External preparation composition comprising fatty acid-based ionic liquid as active ingredient
CN103239721B (en) * 2007-11-22 2016-03-16 美德阿利克斯株式会社 Comprise ion type liquid based on fatty acid as the external preparation composition of active component
EP2223703A4 (en) * 2007-11-22 2011-01-19 Medrx Co Ltd External preparation composition comprising fatty acid-based ionic liquid as active ingredient
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US10441528B2 (en) 2008-02-13 2019-10-15 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US10231923B2 (en) 2009-09-28 2019-03-19 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US10869830B2 (en) 2009-09-28 2020-12-22 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US12042557B2 (en) 2009-09-28 2024-07-23 I2O Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US10159714B2 (en) 2011-02-16 2018-12-25 Intarcia Therapeutics, Inc. Compositions, devices and methods of use thereof for the treatment of cancers
US9707187B2 (en) 2011-09-13 2017-07-18 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
US9707189B2 (en) 2011-09-13 2017-07-18 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
EP2570116A1 (en) * 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
EP2570115A1 (en) * 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10583080B2 (en) 2014-09-30 2020-03-10 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US11840559B2 (en) 2016-05-16 2023-12-12 I2O Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US11214607B2 (en) 2016-05-16 2022-01-04 Intarcia Therapeutics Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD912249S1 (en) 2016-06-02 2021-03-02 Intarcia Therapeutics, Inc. Implant removal tool
USD962433S1 (en) 2016-06-02 2022-08-30 Intarcia Therapeutics, Inc. Implant placement guide
USD835783S1 (en) 2016-06-02 2018-12-11 Intarcia Therapeutics, Inc. Implant placement guide
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11654183B2 (en) 2017-01-03 2023-05-23 Intarcia Therapeutics, Inc. Methods comprising continuous administration of exenatide and co-administration of a drug

Also Published As

Publication number Publication date
ES439113A1 (en) 1977-10-16
DE2528516A1 (en) 1976-01-22
AU8280175A (en) 1977-01-13
NZ178011A (en) 1978-07-28
HU170215B (en) 1977-04-28
NL7507798A (en) 1976-01-07
SE7507414L (en) 1976-01-07
BE831042A (en) 1976-01-05
FR2276832A1 (en) 1976-01-30
IL47634A (en) 1978-07-31
ZA754304B (en) 1977-02-23
FR2276832B1 (en) 1978-10-06
IL47634A0 (en) 1975-10-15
JPS5132724A (en) 1976-03-19
YU170475A (en) 1984-02-29

Similar Documents

Publication Publication Date Title
GB1518683A (en) Pharmaceutical compositions
UA29406C2 (en) Esters of tricyclic amino alcohols
MX9205046A (en) 1H-IMIDAZO- (4,5-C) QUINOLIN-4-AMINAS 1-SUBSTITUTED
BR9407910A (en) Compound pharmaceutical composition use of the compound process of treatment of disorders in the central nervous system and process of preparation of the compound
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
DE69531741D1 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
KR890700125A (en) New benzimidazole derivatives, preparation method thereof and pharmaceutical composition containing the compound
BG102254A (en) Oral fast soluble compositions as dopamine antagonists
DE69940769D1 (en) ORAL LIQUID COMPOSITIONS
MY103943A (en) Orthorhombic ciclosporin crystal form, process for its production and pharmaceutical compositions containing it
ATE66605T1 (en) AQUEOUS MEDICINAL FORMULATIONS OF PIROXICAM MONOHYDRATE.
HUP9802320A2 (en) Macrolides, procedure of the preparation of macrolides, macrolides containing pharmaceutical products
ES460743A1 (en) Preserving liquid antacid medicinal formulations
KR950007857A (en) Rapamycin preparations for oral administration
DE69808938D1 (en) METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITIONS
KR930001903A (en) Ubide carrenone oral aqueous solution preparation
ES450075A1 (en) Stable dispersions of fluorescent whitening agents of the bis-triazinylaminostilbene group in free acid form and method of preparing same
ATE139446T1 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OF EXCITATION STATES AND NERVE DYSFUNCTIONS
JPS5218832A (en) Method of making cosmetic preparation
ATE14437T1 (en) AMINOGLYCOSIDE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND SUCH DERIVATIVES FOR USE AS MEDICINAL PRODUCTS.
GB1314926A (en) Urea-derivatives
GB1359044A (en) Quinoline derivatives
JPS5251362A (en) Preparation of optically active pyrrolidine derivatives
GB1353834A (en) Benzenesulphonamides
GB1291414A (en) Aerosol composition

Legal Events

Date Code Title Description
CSNS Application of which complete specification have been accepted and published, but patent is not sealed